Kura Oncology (NASDAQ:KURA) Upgraded to “Strong-Buy” at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Kura Oncology (NASDAQ:KURA) to a strong-buy rating in a research report released on Tuesday morning,Zacks.com reports.

A number of other equities research analysts also recently issued reports on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $28.00 price objective on shares of Kura Oncology in a research report on Thursday, February 6th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. Scotiabank reduced their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. StockNews.com raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Thursday, February 27th. Finally, Jefferies Financial Group reduced their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Price Performance

Shares of NASDAQ KURA opened at $7.33 on Tuesday. The firm’s 50-day moving average price is $8.10 and its 200-day moving average price is $13.64. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The firm has a market capitalization of $570.01 million, a P/E ratio of -3.11 and a beta of 0.85. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. Equities research analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Activity at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,729 shares of company stock worth $92,307. 5.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently made changes to their positions in the stock. Suvretta Capital Management LLC increased its holdings in shares of Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock worth $149,535,000 after buying an additional 583,155 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Kura Oncology by 14.6% in the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company’s stock worth $41,973,000 after buying an additional 615,211 shares during the last quarter. RA Capital Management L.P. bought a new position in shares of Kura Oncology in the 4th quarter worth $38,769,000. Millennium Management LLC increased its holdings in shares of Kura Oncology by 180.1% in the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock worth $20,618,000 after buying an additional 1,521,954 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Kura Oncology by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after buying an additional 41,535 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.